iShares Biotechnology ETF (NQ:IBB)

207.47 -0.27 (-0.13%)

Delayed Quote Updated: 2:51 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

28 29 Next >

CNBC's Final Trades: NXP Semiconductors, Qualcomm, Deere And This Way To Gain Exposure To Growth Potential ↗

February 01, 2022

On CNBC’s “Halftime Report Final Trades,” Stephen Weiss of Short Hills Capital Partners named NXP Semiconductors NV (NASDAQ: NXPI) as his pick, noting that the company is scheduled to rep

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates ↗

February 01, 2022

After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned.

Via Benzinga

The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program ↗

February 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Small Cap Biotech Stocks: Is it time to start trading? ↗

January 31, 2022

It’s time to trade beaten-up small cap biotech stocks.

Via Talk Markets

The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News ↗

January 31, 2022

The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.

Via Benzinga

Weekly Commentary: The High-Wire Act Has Commenced ↗

January 30, 2022

Geez. I guess it’s been a long time since we’ve experienced a hawkish central banker. Powell needed to talk tough on inflation. Yet he seemed determined to occupy the middle ground. There was no...

Via Talk Markets

The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron ↗

January 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study ↗

January 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Key Price Levels to Watch in the Current Choppy Market ↗

January 26, 2022

Because Monday had such a significant breakdown paired with an end-of-day rally it gave us a temporary support level to watch.

Via Talk Markets

The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data ↗

January 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Major Indices Set a Key Support Level as Commodities Heat Up ↗

January 25, 2022

The market is looking to hold its current price area along with Monday’s low as a new key support level.

Via Talk Markets

The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data ↗

January 25, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech Initiates Study Of Omicron-Based Vaccine Candidate Pfizer,...

Via Benzinga

Watch These Two Symbols as Indictors for a Continued Market Rally ↗

January 24, 2022

If we are looking for the market to continue higher, JNK should hold over $106.48 and VXX should not clear its 200-DMA at $27.99.

Via Talk Markets

The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More ↗

January 23, 2022

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the...

Via Benzinga

Do You Have A Solid Trading Plan? ↗

January 23, 2022

As the stock market corrects and potentially forms a new trend, traders who don’t have strict plans might be wondering what to do next.

Via Talk Markets

The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective ↗

January 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer Study Kura...

Via Benzinga

The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug ↗

January 20, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In...

Via Benzinga

The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data ↗

January 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH)...

Via Benzinga

A Trading Range Within A Trading Range ↗

January 18, 2022

As we now enter the second half of January in a new year, the persistent trading range continues.

Via Talk Markets

The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week ↗

January 16, 2022

Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Swiss...

Via Benzinga

The Daily Biotech Pulse: Bausch Files For Eye Health Unit IPO, LumiraDx Antigen Test Can Detect Omicron, Molecular Partners Discloses Fund Stake ↗

January 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Corvus Says Chinese Angel Pharma Starts Phase 1/2 Blood Cancer Study Corvus...

Via Benzinga

The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact ↗

January 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio...

Via Benzinga

The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award ↗

January 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen...

Via Benzinga

How Biotech Confirmed A Reversal Pattern in Both Price and Momentum ↗

January 11, 2022

For roughly three months the biotechnology ETF IBB has been trending lower. Though it’s made multiple attempts to clear the 50-Day moving average, it has failed.

Via Talk Markets

The Daily Biotech Pulse: Illunina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In ↗

January 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BioAtla, Bristol-Myers Squibb Announce Collaboration To Evaluate ADC-Opdivo...

Via Benzinga

Could Greece (GREK) be Waking Up? ↗

January 10, 2022

While the major indices were selling off Monday, GREK held near an important breakout area.

Via Talk Markets

The Week Ahead In Biotech (Jan 10-15): JPMorgan Healthcare Conference Front And Center, Preannouncements Keep Coming ↗

January 10, 2022

Biotech stocks came under selling pressure along with the broader market, as rate hike fears seized Wall Street. The news flow, however, was scanty. Last week, the Food and Drug...

Via Benzinga

There Is A Skip In The Song ↗

January 09, 2022

Early January is when we should always be prepared for a skip in the song playing in the market's narrative. The 2022

Via Talk Markets

The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs ↗

January 07, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hepion's Lead NASH Drug Candidate Gets The Non-Proprietary Name...

Via Benzinga

The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales ↗

January 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Illumina Announces Co-Development Partnership With SomaScan For Accelerating...

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

28 29 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.